The Latest Breaking News from Quoin Pharmaceuticals

Gainers

Upgrades

The FDA has accepted Quoin Pharmaceuticals Inc's (NASDAQ:QNRX) Investigational New Drug (IND) application for its licensed formulation, which uses Skinvisible Inc's (OTC:SKVI) Invisicare drug delivery technology.  The topical formulation "QRX003" was developed to treat Netherton's Syndrome, a debilitating hereditary disorder that affects the skin, hair, and the immune system. Skinvisible granted Quoin an exclusive, royalty-bearing…

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.

Quoin Pharmaceuticals (NASDAQ: QNRX) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate clinical testing for its Investigational New Drug application for QRX003.